5 results on '"Torres, Juan Pablo"'
Search Results
2. Plasma metabolomics and clinical predictors of survival differences in COPD patients
- Author
-
Pinto-Plata, Victor, Casanova, Ciro, Divo, Miguel, Tesfaigzi, Yohannes, Calhoun, Vince, Sui, Jing, Polverino, Francesca, Priolo, Carmen, Petersen, Hans, de Torres, Juan Pablo, Marin, Jose Maria, Owen, Caroline A., Baz, Rebeca, Cordova, Elizabeth, and Celli, Bartolome
- Published
- 2019
- Full Text
- View/download PDF
3. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease.
- Author
-
Divo, Miguel J., Marin, José M., Casanova, Ciro, Cabrera Lopez, Carlos, Pinto-Plata, Victor M., Marin-Oto, Marta, Polverino, Francesca, de-Torres, Juan P., Billheimer, Dean, Celli, Bartolome R., The BODE Collaborative Group, Macario, Ciro Casanova, Pinto-Plata, Victor, de-Torres, Juan Pablo, Lopez, Carlos Cabrera, Oto, Marta Marin, and BODE Collaborative Group
- Abstract
Rationale and Objective: Patients with chronic obstructive pulmonary disease (COPD), usually diagnosed after the 6th decade, frequently suffer from comorbidities. Whether COPD patients 50 years or younger (Young COPD) have similar comorbidities with the same frequency and mortality impact as aged-matched controls or older COPD patients is unknown.Methods: We compared comorbidity number, prevalence and type in 3 groups of individuals with ≥ 10 pack-years of smoking: A Young (≤ 50 years) COPD group (n = 160), an age-balanced control group without airflow obstruction (n = 125), and Old (> 50 years) COPD group (n = 1860). We also compared survival between the young COPD and control subjects. Using Cox proportional model, we determined the comorbidities associated with mortality risk and generated Comorbidomes for the "Young" and "Old" COPD groups.Results: The severity distribution by GOLD spirometric stages and BODE quartiles were similar between Young and Old COPD groups. After adjusting for age, sex, and pack-years, the prevalence of subjects with at least one comorbidity was 31% for controls, 77% for the Young, and 86% for older COPD patients. Compared to controls, "Young" COPDs' had a nine-fold increased mortality risk (p < 0.0001). "Comorbidomes" differed between Young and Old COPD groups, with tuberculosis, substance use, and bipolar disorders being distinct comorbidities associated with increased mortality risk in the Young COPD group.Conclusions: Young COPD patients carry a higher comorbidity prevalence and mortality risk compared to non-obstructed control subjects. Young COPD differed from older COPD patients by the behavioral-related comorbidities that increase their risk of premature death. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort
- Author
-
AstraZeneca, Calle Rubio, Myriam, Rodríguez Hermosa, Juan Luis, Torres, Juan Pablo de, Marín, José María, Martínez-González, Cristina, Fuster, Antonia, Cosio, Borja G., Peces-Barba, Germán, Solanes, Ingrid, Feu-Collado, Nuria, López-Campos, J. L., Casanova, Ciro, AstraZeneca, Calle Rubio, Myriam, Rodríguez Hermosa, Juan Luis, Torres, Juan Pablo de, Marín, José María, Martínez-González, Cristina, Fuster, Antonia, Cosio, Borja G., Peces-Barba, Germán, Solanes, Ingrid, Feu-Collado, Nuria, López-Campos, J. L., and Casanova, Ciro
- Abstract
[Background] Control in COPD is a dynamic concept that can reflect changes in patients’ clinical status that may have prognostic implications, but there is no information about changes in control status and its long-term consequences., [Methods] We classified 798 patients with COPD from the CHAIN cohort as controlled/uncontrolled at baseline and over 5 years. We describe the changes in control status in patients over long-term follow-up and analyze the factors that were associated with longitudinal control patterns and related survival using the Cox hazard analysis., [Results] 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 (52.1%) changed control status during follow-up. The variables significantly associated with persistent control were not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All-cause mortality was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all-cause mortality was 2.274 (95% CI 1.394–3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow-up period, 20% had scaled up their treatment, with triple therapy being the most frequent therapeutic pattern., [Conclusions] The evaluation of COPD control status provides relevant prognostic information on survival. There is important variability in clinical control status and only a small proportion of the patients had persistently good control. Changes in the treatment pattern may be relevant in the longitudinal pattern of COPD clinical control. Further studies in other populations should validate our results., [Trial registration] Clinical Trials.gov: identifier NCT01122758.
- Published
- 2021
5. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice.
- Author
-
Torres, Juan Pablo, Gomez, Ana M., Khokhar, Shama, Bhoj, Vijay G., Tagliabue, Claudia, Chang, Michael L., Kiener, Peter A., Revell, Paula A., Ramilo, Octavio, and Mejias, Asuncion
- Subjects
- *
IMMUNOGLOBULINS , *RESPIRATORY syncytial virus , *ANTIGENS , *MACROPHAGES , *CYTOKINES , *BIOLOGICAL models , *RESEARCH , *VIRAL load , *ANIMAL experimentation , *RESEARCH methodology , *RNA , *MEDICAL cooperation , *EVALUATION research , *SEVERITY of illness index , *COMPARATIVE studies , *PULMONARY function tests , *RESPIRATORY syncytial virus infections , *CELL lines , *MICE - Abstract
Background: Respiratory Syncytial Virus (RSV) infection is usually restricted to the respiratory epithelium. Few studies have documented the presence of RSV in the systemic circulation, however there is no consistent information whether virus detection in the blood correlates with disease severity.Methods: Balb/c mice were inoculated with live RSV, heat-inactivated RSV or medium. A subset of RSV-infected mice was treated with anti-RSV antibody 72 h post-inoculation. RSV RNA loads were measured by PCR in peripheral blood from day 1-21 post-inoculation and were correlated with upper and lower respiratory tract viral loads, the systemic cytokine response, lung inflammation and pulmonary function. Immunohistochemical staining was used to define the localization of RSV antigens in the respiratory tract and peripheral blood.Results: RSV RNA loads were detected in peripheral blood from day 1 to 14 post-inoculation, peaked on day 5 and significantly correlated with nasal and lung RSV loads, airway obstruction, and blood CCL2 and CXCL1 expression. Treatment with anti-RSV antibody reduced blood RSV RNA loads and improved airway obstruction. Immunostaining identified RSV antigens in alveolar macrophages and peripheral blood monocytes.Conclusions: RSV RNA was detected in peripheral blood upon infection with live RSV, followed a time-course parallel to viral loads assessed in the respiratory tract and was significantly correlated with RSV-induced airway disease. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.